SYRE - CIK 0001636282
The table below shows Spyre Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $85.72M | $89.42M | $188.89M | $34.86M | $15.14M | $90.09M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $777.78M |
| $608.47M |
| $341.53M |
| $62.26M |
| $98.89M |
| $149.79M |
| Property, plant & equipment | - | - | $0.00 | $3.22M | $4.55M | $5.64M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $777.78M | $608.48M | $341.86M | $71.14M | $109.93M | $161.62M |
| Accounts payable | - | - | - | $677.00K | $3.32M | $2.25M |
| Total current liabilities | $58.69M | $54.06M | $31.98M | $14.66M | $20.14M | $16.44M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $62.55M | $90.68M | $73.29M | $20.84M | $25.98M | $21.79M |
| Retained earnings | -$1.13B | -$972.43M | -$764.41M | -$425.62M | -$341.81M | -$276.01M |
| Total equity | $715.24M | $517.80M | $184.02M | $50.30M | $83.94M | $139.83M |